Title
Category
Credits
Event date
Cost
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Introductory Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Radiology Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Neurology Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionOver 80% of patients with multiple sclerosis (MS) experience related spasticity. This symptom can be debilitating for both physical and non-physical daily function. Yet, despite the high prevalence and impact of spasticity, a substantial portion of affected patients remain unrecognized and undertreated.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Primary Care Module
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Across the Spectrum: Transforming the Detection and Management of Disease State Transitions Across the Spectrum of Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionMultiple sclerosis (MS) is a disease of transitions from subclinical changes to isolated events to definite MS. These clinical developments are often accompanied by changes in disease states ranging from active to inactive. But with increasing recognition that progressive pathologies may begin early in MS, the lines between disease states are beginning to blur.
Inside Myasthenia Gravis: Where Providers and Patients Diverge on Defining Treatment Success
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionThe understanding and prognosis of patients with myasthenia gravis (MG) have made dramatic leaps since the advent of serological evaluation and immunotherapy. In fact, clinicians have become so confident in the ability to diagnose and manage MG that prominent medical organizations commonly boast the ability of these patients to lead “normal lives.” However, studies find that clinician and patient perceptions are often not the same.
Deciphering Neuromyelitis Optica Spectrum Disorder: Addressing Real Clinician Questions Concerning Diagnosis and Management
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Attendance
$0.00
OverviewThough neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still cause it to be confused with multiple conditions such as multiple sclerosis (MS), leading to inappropriate and even harmful treatment. The emergence of similarly presenting MOG antibody disease (MOGAD) as its own entity has further complicated the picture.

Pages